title: Microglial activation is not prevented by tacrolimus but dopamine neuron damage is reduced in a rat model of Parkinson's disease progression.
abstract: A progressive model of Parkinson's disease has been recently developed in the rat where a unilateral excitotoxic injection into the globus pallidus leads to a gradual loss of dopaminergic neurons in the ipsilateral substantia nigra over a period of at least 6 weeks. In this model microglial activation is observed in the ipsilateral substantia nigra 3 weeks after the lesion and could contribute to neuronal death at this time. The immunosuppressant drug tacrolimus (FK506) reduces dopamine cell death at 3 weeks following a globus pallidus lesion, but not thereafter. Tacrolimus-mediated neuroprotection could result from suppression of microglial activation but the microglial activation at three weeks post-lesion was not much reduced. Microglial activation was observed even in the apparent absence of neuronal death, prompting the suggestion that tacrolimus may prevent, or at least delay, the release of toxic cytokines from activated microglia. By 6 weeks after the GP lesion, even this mechanism fails to protect the dopamine cells from damage.
authors.affiliation: University of Edinburgh, Division of Neuroscience, Veterinary Biological Sciences, Summerhall, Edinburgh, EH9 1QH, UK.
authors.forename: Ann K
authors.initials: AK
authors.lastname: Wright
authors.forename: Clare
authors.initials: C
authors.lastname: Miller
authors.forename: Maya
authors.initials: M
authors.lastname: Williams
authors.forename: Gordon
authors.initials: G
authors.lastname: Arbuthnott
mesh_terms: D000818:Animals; D016923:Cell Death / Q000187:drug effects; D004195:Disease Models, Animal; D018450:Disease Progression; D004298:Dopamine / Q000378:metabolism; D005911:Gliosis / Q000473:pathology / Q000517:prevention & control; D005917:Globus Pallidus / Q000187:drug effects / Q000473:pathology; D017628:Microglia / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D009474:Neurons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010300:Parkinson Disease / Q000276:immunology / Q000473:pathology* / Q000517:prevention & control; D051381:Rats; D013378:Substantia Nigra / Q000187:drug effects / Q000473:pathology*; D016559:Tacrolimus / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D018696:Neuroprotective Agents; D004298:Dopamine; D016559:Tacrolimus